The quest for the “holy grail” of cardiovascular therapy - a drug that dramatically lowered LDL-c and raised HDL-c and which would hopefully reverse atherosclerosis - has ended ignominiously.
from Forbes Real Time https://www.forbes.com/sites/johnlamattina/2017/10/17/the-blockbuster-that-wasnt-a-cetp-inhibitor-post-mortem/
via IFTTT
No comments:
Post a Comment